molecules of the month


oral picomolar & reversible CDK7 inhibitor

Ph. I candidate in breast cancer comb. Therapy

from previous CDK7 inhibitor SY-1365

Journal of Medicinal Chemistry

Syros Pharmaceuticals Inc.

Chemical structure of molecule SY-5609 Syros Pharmaceuticals CDK7 kinase inhibitor
1 min read

4. The Syros Pharmaceuticals CDK7 kinase inhibitor, SY-5609, is a picomolar, reversible, and highly selective molecule with slow off-rate kinetics.  It follows a prior covalent clinical candidate from Syros. The molecule is >4000x selective vs. the nearest known off-target among 485 kinases profiled. Cyclin-dependent kinase inhibitors have seen a resurgence in interest recently as previous issues with family selectivity and potential toxicity now seem surmountable. This is thanks to a combination of biomarker-focused clinical development and the success of combination regimens and patient selection for CDK4/6 inhibitors as well as wealth of industry kinase drug discovery experience. This inhibitor is a rare example of a phosphine-oxide containing clinical candidate, though the motif is likely to be more frequently used due to…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: